A column by Kojo Koram in The Guardian says that companies have moved quickly to supply cannabis in the United Kingdom as a wellness treatment, while patients with serious illnesses are unable to obtain prescriptions for the drug through the National Health Service. The column's headline describes the UK's legal cannabis market as booming.
According to the column, Louis Petit, a young artist, was "effectively exiled" in the Netherlands as a teenager so that he could access the medical cannabis he needed to control his epilepsy. The summary reports that in 2022 Petit was preparing to return to the UK. The material available for this report does not say where he was living at the time of writing or whether he has since returned.
The column's summary then refers to events that occurred six years earlier, at which point the text available for this report ends. As a result, the column's full account of that earlier period, and any further details of Petit's treatment, are not included in the material reviewed here.
The column presents Petit's case alongside the growth of the commercial cannabis market. It sets the expansion of companies selling the drug as a wellness product against the limited access available to patients who need it for serious medical conditions. The summary does not identify the companies involved.
The material reviewed for this report includes no response from the NHS, the UK government, or any company operating in the market, so the positions of those bodies are not reported here. The piece is an opinion column, and this account reports only the claims and descriptions it contains, as published by The Guardian in its Comment is free section.